Thrombospondin-1 expression in breast cancer: Prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components

Histology and Histopathology

Volumn 27, Issue 2, 2012, Pages 209-216

  Ioachim, E ^a   Damala, K ^a   Tsanou, E ^a   Briasoulis, E ^b   Papadiotis, E ^a   Mitselou, A ^a   Charhanti, A ^a   Doukas, M ^a   Lampri, L ^a   Arvanitis, D L ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Angiogenesis; Breast cancer; Extracellular matrix; P 53; Thrombospondin 1

Indexed keywords

PROTEIN P53; THROMBOSPONDIN 1; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; EXTRACELLULAR MATRIX; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; THROMBOSPONDIN 1; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857763650     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Asch A.S., Barnwell J. and Silverstein R.L. (1987). Isolation of the thrombospondin membrane receptor. J. Clin. Invest. 79, 1054-1061.
2. Bertin N., Clezardin P., Kubiak R. and Frappart L. (1997). Thrombospondin-1 and-2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res. 57, 396-399.
3. BenEzra D., Griffin B.W., Maftzir G. and Aharonov O. (1993). Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest. Ophthalmol. Vis. Sci. 34, 3601-3608.
4. Chen H., Herndon M.E. and Lawler J. (2000). The cell biology of thrombospondin-1. Matrix Biol. 19, 597-614.
5. Clezardin P., Frappart L., Clerget M., Pechoux C. and Delmas P.D. (1993). Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic and neoplastic human breast. Cancer Res. 53, 1421-1430.
6. Corless C.L., Mendosa A., Collins T. and Lawler J. (1992). Co localization of thrombospondin and syndecan during murine development. Dev. Dynam. 193, 346-358.
7. Dameron K.M., Volpert O.V., Tainsky M.A. and Bouck N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
8. Elston C.W. and Ellis I.O. (1991). Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 19, 403-410.
9. Gasparini G., Toi M., Biganzoli E., Dittadi R., Fanelli M., Morabito A., Boracchi P. and Gion M. (2001). Thrombospondin-1 and -2 in node negative breast cancer: correlation with angiogenenic factors, p53, cathepsin D, hormon receptors and prognosis. Oncology 60, 72-80.
10. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., Dunn M., Nichols P.W., Taylor C.R., Skinner D.G. and Cote R.J. (1997). Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. 89, 219-227.
11. Hyder S.M., Liang Y. and Wu J. (2009). Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int. J. Cancer 125, 1045-1053.
12. Ioachim E. (2008). Thymidine phosphorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components. Histol. Histopathol. 23, 187-196.
13. Ioachim E., Charchanti A., Briasoulis E., Karavasilis V., Tsanou H., Arvanitis D.L., Agnantis N.J. and Pavlidis N. (2002). Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 38, 2362-2370.
14. Linderholm B.K., Lindahl Th., Holmberg L., Klaar S., Lennerstrand J., Henriksson R. and Bergh J. (2001). The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61, 2256-2260.
15. Linderholm B., Karlsson E., Klaar S., Lindahl Th., Borg A-L., Elmberger G. and Bergh J. (2004). Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancer. Eur. J. Cancer 40, 2417-2423.
16. Poller D.N., Roberts E.C., Bell J.A., Elston C.W., Blamey R.W. and Ellis I.O. (1993). p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum. Pathol. 24, 463-468.
17. Pratt D., Miller W. and Dawes J. (1989). Thrombospondin in malignant and non-malignant breast tissue. Eur. J. Cancer Clin. Oncol. 25, 343-350.
18. Qian X. and Tuszynski G.P. (1996). Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc. Soc. Exp. Biol. Med. 212, 199-207.
19. Rak J. and Klement G. (2000). Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 19, 93-96.
20. Rice A.J., Steward M.A. and Quinn C.M. (2002). Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J. Clin. Pathol. 55, 921-925.
21. Serre Cl-M., Clezardin P., Frappart L, Boivin G. and Delmas P. D. (1995). Distribution of thrombospondin and integrin ·v in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy. Virchows Arch. 427, 365-372.
22. Simantov R., Febbraio M., Crombie R., Asch A.S., Nachman R.L. and Silverstain R.L. (2001). Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J. Clin. Invest. 107, 45-52.
23. Steward M.A., Rice A.J., Roberts D., Benson K., Horgan K. and Quinn C.M. (1998). Thrombospondin-1 in invasive breast cancer and its association with p53 expression, microvessel density and clinical outcome. J. Pathol. 184, 5A.
24. Taraboletti G., Roberts D. and Liotta L.A. (1987). Thrombospondininduced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J. Cell Biol. 105, 2409-2415.
25. Tsanou E., Ioachim E., Briasoulis E., Damala K., Charchanti A., Karavasilis V., Pavlidis N. and Agnantis N.J. (2004). Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components and survival. J. Exp. Clin. Cancer Res. 23, 641-650.
26. Tokyol C., Ersoz G., Dilek F.H., Gencer E., Kosar M.N. and Dilek O.N. (2009). Thrombospondin -1 expression and angiogenesis in breast carcinoma and their relation with platelet activity. Ups. J. Med. Sci. 114, 108-115.
27. Tuszynski G.P. and Nicosia R.F. (1994). Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab. Invest. 70, 228-233.
28. Volpert O.V., Stellmach V. and Bouck N. (1995). The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat. 36, 119-126.
29. Wang-Rodriguez J., Urquidi V., Rivard A. and Goodison S. (2003). Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is mot indicative of metastatic status. Breast Cancer Res. 5, 136-143.
30. Wong S.Y., Purdie A.T. and Han P. (1992). Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am. J. Pathol. 140, 1473-1482.
31. Yee K.O., Connolly C.M., Duquette M., Kazerounian, S., Washington R. and Lawler J. (2009). The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res. Treat. 114, 85-96.
32. Zabrenetzky V., Harris C.C., Steeg P.S. and Roberts D.D. (1994). Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59, 191-195.